



Wikipedia - Diphenhydramine

For United Nations Operation in Somalia, see [UNOSOM](#).

Diphenhydramine



Clinical data

Pronunciation [/ˌdaɪfənˈhaɪdrəmiːn/](#)

Trade names [Benadryl](#), Unisom, [Sominex](#), others

AHFS/Drugs.com [Monograph](#)

MedlinePlus [a682539](#)

Pregnancy AU: [A](#)

category	US: B (No risk in non-human studies)
Dependence liability	Very low
Routes of administration	By mouth, IM , IV , topical and rectal
ATC code	D04AA32 (WHO) D04AA33 (WHO), R06AA02 (WHO)
Legal status	
Legal status	AU: S2 (Pharmacy only) US: OTC
Pharmacokinetic data	
Bioavailability	40–60% ^[1]
Protein binding	98–99%
Metabolism	Various cytochrome P450 liver enzymes: CYP2D6 (80%), 3A4 (10%) ^[4]
Biological half-life	7 hours (children) ^[2] 12 hours (adults) ^[2] 17 hours (elderly) ^[2]
Excretion	94% through the urine, 6% through feces ^[3]
Identifiers	
IUPAC name [show]	
CAS Number	58-73-1 ✓
PubChem CID	3100
IUPHAR/BPS	1224
DrugBank	DB01075 ✓
ChemSpider	2989 ✓

UNII	8GTS82S83M
KEGG	D00669 ✖
ChEBI	CHEBI:4636 ✔
ChEMBL	ChEMBL657 ✔
ECHA InfoCard	100.000.360
Chemical and physical data	
Formula	C ₁₇ H ₂₁ NO
Molar mass	255.355 g/mol
3D model (Jmol)	Interactive image
SMILES [show]	
InChI [show]	
✖✔ (what is this?) (verify)	

Diphenhydramine is an [antihistamine](#) mainly used to treat [allergies](#).^[5] It is also used for [insomnia](#), symptoms of the [common cold](#), tremor in [parkinsonism](#), and [nausea](#).^[5] It is used by mouth, [injection into a vein](#), and [injection into a muscle](#).^[5] Maximal effect is typically around two hours after a dose and effects can last for up to seven hours.^[5]

Common side effects include sleepiness, poor coordination, and an upset stomach.^[5] Its use is not recommended in babies.^[5] There is no clear risk of harm when used during [pregnancy](#); however, use during [breastfeeding](#) is not recommended.^[6] It is a [first generation H1-antihistamine](#) and works by blocking certain effects of [histamine](#).^[5]

Diphenhydramine was made by [George Rieveschl](#) and came into commercial use in 1946.^{[7][8]} It is available as a [generic medication](#).^[5] The wholesale price in the developing world as of 2014 is about [US\\$0.01](#) per dose.^[9] In the United States, it costs less than [US\\$25](#) for a typical month supply.^[10] It is sold under the trade name Benadryl among others.^[5]

Medical uses[[edit](#)]

Diphenhydramine is a first-generation antihistamine used to treat a number of conditions including [allergic](#) symptoms and [itchiness](#), the [common cold](#), [insomnia](#), [motion sickness](#), and [extrapyramidal symptoms](#).^{[11][12]} Diphenhydramine also has [local anesthetic](#) properties, and has been used as such in people allergic to common [local anesthetics](#) such as [lidocaine](#).^[13]

Allergies[[edit](#)]

Diphenhydramine is effective in treatment of allergies.^[14] As of 2007 it was the most commonly used antihistamine for acute allergic reactions in the emergency department.^[15]

By injection it is often used in addition to [epinephrine](#) for [anaphylaxis](#).^[16] Its use for this purpose had not been properly studied as of 2007.^[17] Its use is only recommended once acute symptoms have improved.^[14]

Topical formulations of diphenhydramine are available, including creams, lotions, gels, and sprays. These are used to relieve itching, and have the advantage of causing fewer systemic effects (e.g., drowsiness) than oral forms.^[18]

Movement disorders[\[edit\]](#)

Diphenhydramine is used to treat [Parkinson's disease-like extrapyramidal symptoms](#) caused by [antipsychotics](#).^[19]

Sleep[\[edit\]](#)

Because of its [sedative](#) properties, diphenhydramine is widely used in nonprescription sleep aids for insomnia. The drug is an ingredient in several products sold as sleep aids, either alone or in combination with other ingredients such as [acetaminophen](#) (paracetamol). An example of the latter is [Tylenol PM](#). Diphenhydramine can cause minor psychological dependence.^[20] Diphenhydramine can cause [sedation](#) and has also been used as an [anxiolytic](#).^[21]


Nausea[\[edit\]](#)

Diphenhydramine also has [antiemetic](#) properties, which make it useful in treating the nausea that occurs in [vertigo](#) and motion sickness.^[22]

Adverse effects[\[edit\]](#)

The most prominent side effect is sedation. A typical dose creates driving impairment equivalent to a blood-alcohol level of 0.1 which is higher than the 0.08 limit of most drunk driving laws.^[15]

Diphenhydramine is a potent [anticholinergic](#) agent. This activity is responsible for the [side effects](#) of dry mouth and throat, [increased heart rate](#), [pupil dilation](#), [urinary retention](#), constipation, and, at high doses, hallucinations or [delirium](#). Other side effects include motor impairment ([ataxia](#)), flushed skin, blurred vision at nearpoint owing to lack of accommodation ([cycloplegia](#)), abnormal sensitivity to bright light ([photophobia](#)), sedation, difficulty concentrating, short-term memory loss, visual disturbances, irregular breathing, dizziness, irritability, itchy skin, confusion, increased body temperature (in general, in the hands and/or feet), temporary [erectile dysfunction](#), and excitability, and although it can be used to treat nausea, higher doses may cause vomiting.^[23] Some side effects, such as [twitching](#), may be delayed until the drowsiness begins to cease and the person is in more of an awakening mode.



[*Torsades de pointes*](#) can occur as a side effect of diphenhydramine

Acute poisoning can be fatal, leading to cardiovascular collapse and death in 2–18 hours, and in general is treated using a symptomatic and supportive approach.^[24] Diagnosis of toxicity is based on history and clinical presentation, and in general specific levels are not useful.^[25] Several levels of evidence strongly indicate diphenhydramine (similar to [chlorpheniramine](#)) can block the [delayed rectifier potassium channel](#) and, as a consequence, prolong the [QT interval](#), leading to [cardiac arrhythmias](#) such as [torsades de pointes](#).^[26] No specific [antidote](#) for diphenhydramine toxicity is known, but the anticholinergic syndrome has been treated with [physostigmine](#) for severe delirium or tachycardia.^[25] [Benzodiazepines](#) may be administered to decrease the likelihood of [psychosis](#), [agitation](#), and [seizures](#) in patients who are prone to these symptoms.^[27]

Some patients have an allergic reaction to diphenhydramine in the form of [hives](#).^{[28][29]} However, [restlessness](#) or [akathisia](#) can also be a side effect made worse by increased levels of diphenhydramine, especially with recreational dosages.^[30] As diphenhydramine is extensively metabolized by the [liver](#), caution should be exercised when giving the drug to individuals with hepatic impairment.

Long term anticholinergic use is associated with an increased risk for cognitive decline and dementia among older people.^[31]

Special populations[[edit](#)]

Diphenhydramine is not recommended for patients older than 60 or children under the age of six, unless a physician is consulted.^{[32][33]} These populations should be treated with second-generation antihistamines such as [loratadine](#), [desloratadine](#), [fexofenadine](#), [cetirizine](#), [levocetirizine](#), and [azelastine](#).^[24] Due to its strong anticholinergic effects, diphenhydramine is on the "[Beers list](#)" of drugs to avoid in the elderly.^{[34][35]}

Diphenhydramine is category B in the [FDA Classification of Drug Safety During Pregnancy](#).^[36] It is also excreted in breast milk.^[37] [Paradoxical reactions](#) to diphenhydramine have been documented, in particular among children, and it may cause excitation instead of sedation.^[30]

Topical diphenhydramine is sometimes used especially on patients in hospice. This use is without indication and topical diphenhydramine should not be used as treatment for nausea because research does not indicate this therapy is more effective than alternatives.^[38]

Measurement in body fluids[[edit](#)]

Diphenhydramine can be quantified in blood, plasma, or serum.^[39] [Gas chromatography](#) with [mass spectrometry](#) (GC-MS) can be used with [electron ionization](#) on full scan mode as a screening test. GC-MS or GC-NDP can be used for quantification.^[39] Rapid urine drug screens using immunoassays based on the principle of competitive binding may show false-positive [methadone](#) results for patients having ingested diphenhydramine.^[40] Quantification can be used to monitor therapy, confirm a diagnosis of poisoning in hospitalized patients, provide evidence in an impaired driving arrest, or assist in a death investigation.^[39]

Mechanism of action[[edit](#)]

Overview of diphenhydramine targets and effects		
Biological target	Mode of action	Effect
H₁ receptor (Peripheral)	Inverse agonist	Allergy reduction
H ₁ receptor (Central)	Antagonist	Sedation
mAChR Receptors	Competitive antagonist	Anticholinergic Antiparkinson
Na channel	Blocker	Local anesthetic
SERT	Inhibitor	Mood alteration

Diphenhydramine is an [inverse agonist](#) of the [histamine H₁ receptor](#).^[41] It is a member of the [ethanolamine](#) class of antihistaminergic agents.^[24] By reversing the effects of histamine on the [capillaries](#), it can reduce the intensity of [allergic symptoms](#). It also crosses the [blood–brain barrier](#) and [inversely agonizes](#) the H₁ receptors [centrally](#).^[41] Its effects on central H₁ receptors cause drowsiness.

Like many other first-generation antihistamines, diphenhydramine is also a potent [antimuscarinic](#) (a [competitive antagonist](#) of [muscarinic acetylcholine receptors](#)) and, as such, at high doses can cause [anticholinergic syndrome](#).^[42] The utility of diphenhydramine as an [antiparkinson](#) agent is the result of its blocking properties on the muscarinic acetylcholine receptors in the brain.

Diphenhydramine also acts as an intracellular [sodium channel blocker](#), which is responsible for its actions as a [local anesthetic](#).^[43] Diphenhydramine has also been shown to inhibit the reuptake of [serotonin](#).^[44] It has been shown to be a [potentiator](#) of [analgesia](#) induced by [morphine](#), but not by [endogenous opioids](#), in rats.^[45]

Pharmacokinetics[[edit](#)]

Oral [bioavailability](#) of diphenhydramine is in the range of 40–60% and peak plasma concentration occurs about 2–3 hours after administration.^[1] The primary route of metabolism is two successive [demethylations](#) of the [tertiary amine](#). The resulting primary amine is further [oxidized](#) to the [carboxylic acid](#).^[1] The [half-life](#) is as short as 8 hours in children to 17 hours in the elderly.^[2]

History[[edit](#)]

Diphenhydramine was discovered in 1943 by [George Rieveschl](#), a former professor at the [University of Cincinnati](#).^{[46][47]} In 1946, it became the first prescription antihistamine approved by the U.S. FDA.^[48]

In the 1960s, diphenhydramine was found to inhibit [reuptake](#) of the [neurotransmitter serotonin](#).^[44] This discovery led to a search for viable [antidepressants](#) with similar structures and fewer side effects, culminating in the invention of [fluoxetine](#) (Prozac), a [selective serotonin reuptake inhibitor](#) (SSRI).^{[44][49]} A similar search had previously led to the synthesis of the first SSRI, [zimelidine](#), from [brompheniramine](#), also an antihistamine.^[50]

Society and culture[[edit](#)]

Diphenhydramine is sometimes used recreationally as a [deliriant](#), or as a potentiator of [alcohol](#),^{[51][52]} opiates,^[53] [DXM](#) and other [depressants](#). Diphenhydramine is deemed to have limited abuse potential in the United States due to its potentially serious side-effect profile and limited euphoric effects, and is not a controlled substance. Since 2002, the U.S. FDA has required special labeling warning against use of multiple products that contain diphenhydramine.^[54] In some jurisdictions, diphenhydramine is often present in postmortem specimens collected during investigation of sudden infant deaths; the drug may play a role in these events.^{[55][56]}

Diphenhydramine is among prohibited and controlled substances in the [Republic of Zambia](#),^[57] and travelers are advised not to bring the drug into the country. Several Americans have been detained by the Zambian Drug Enforcement Commission for possession of Benadryl and other over-the-counter medications containing diphenhydramine.^[58]

[Procter & Gamble](#) markets an over-the-counter formulation of diphenhydramine as a [sleep-aid](#) under the brand "ZzzQuil". In 2014, this product had annual sales of over \$120 million, and had a 29.3% share of the \$411 million sleep-aid market category.^[59]

Recreational use[[edit](#)]

Diphenhydramine is sometimes used as a recreational drug, often by those without access to illegal drugs.^[60] Recreational use of diphenhydramine may cause:^[61]

- Dysphoria

- Hallucinations (auditory, visual, etc.)
- Heart palpitations
- Extreme drowsiness
- Severe dizziness
- Abnormal speech (inaudibility, forced speech, etc.)
- Flushed skin
- Severe mouth and throat dryness
- Tremors
- Seizures
- Inability to urinate
- Vomiting
- Motor disturbances
- Anxiety/nervousness
- Disorientation
- Abdominal pain
- Delirium
- Coma
- Death

Names[[edit](#)]

Diphenhydramine is marketed under the trade name [Benadryl](#) by [McNeil Consumer Healthcare](#) in the U.S., Canada, and South Africa (trade names in other countries include Dimedrol, Daedalon, and Nytol). It is also available as a [generic](#) medication.

References[[edit](#)]

1. [^] [Jump up to: ^{a b c} Paton DM, Webster DR \(1985\). "Clinical pharmacokinetics of H1-receptor antagonists \(the antihistamines\)". *Clin. Pharmacokinet.* **10** \(6\): 477–97. \[doi:10.2165/00003088-198510060-00002\]\(#\). \[PMID 2866055\]\(#\).](#)
2. [^] [Jump up to: ^{a b c d} Simons KJ, Watson WT, Martin TJ, Chen XY, Simons FE \(July 1990\). "Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children". *J. Clin. Pharmacol.* **30** \(7\): 665–71. \[doi:10.1002/j.1552-4604.1990.tb01871.x\]\(#\). \[PMID 2391399\]\(#\).](#)
3. [Jump up ^](#) Garnett WR (February 1986). "Diphenhydramine". *Am. Pharm. NS26* (2): 35–40. [PMID 3962845](#).
4. [Jump up ^](#) "[Showing Diphenhydramine \(DB01075\)](#)". DrugBank. Retrieved 5 September 2009.
5. [^] [Jump up to: ^{a b c d e f g h i} "Diphenhydramine Hydrochloride". *Drugs.com*. American Society of Health-System Pharmacists. 6 September 2016. Retrieved 28 September 2016.](#)
6. [Jump up ^](#) "[Diphenhydramine Pregnancy and Breastfeeding Warnings](#)". *Drugs.com*. Retrieved 28 September 2016.
7. [Jump up ^](#) Dörwald, Florencio Zaragoza (2013). *Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds*. John Wiley & Sons. p. 225. [ISBN 9783527645657](#).
8. [Jump up ^](#) "[Benadryl](#)". Ohio History Central. Retrieved 28 September 2016.
9. [Jump up ^](#) "[Diphenhydramine](#)". *International Drug Price Indicator Guide*. Retrieved 28 September 2016.
10. [Jump up ^](#) Hamilton, Richart (2015). *Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition*. Jones & Bartlett Learning. p. 240. [ISBN 9781284057560](#).
11. [Jump up ^](#) "[Diphenhydramine Hydrochloride Monograph](#)". *Drugs.com*. The American Society of Health-System Pharmacists.

12. [Jump up](#) [^] Brown HE, Stoklosa J, Freudenreich O (December 2012). "[How to stabilize an acutely psychotic patient](#)" (PDF). *Current Psychiatry*. **11** (12): 10–16. Archived from [the original](#) (PDF) on 14 May 2013.
13. [Jump up](#) [^] Smith DW, Peterson MR, DeBerard SC (August 1999). "Local anesthesia. Topical application, local infiltration, and field block". *Postgrad. Med.* **106** (2): 57–60, 64–6. [doi:10.3810/pgm.1999.08.650](#). [PMID 10456039](#).
14. [^] [Jump up to: ^a ^b](#) American Society of Health-System Pharmacists. "[Diphenhydramine Hydrochloride](#)". *Drugs.com*. Retrieved 2 August 2016.
15. [^] [Jump up to: ^a ^b](#) Banerji, A; Long, AA; Camargo CA, Jr (2007). "Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature review.". *Allergy and Asthma Proceedings*. **28** (4): 418–26. [doi:10.2500/aap.2007.28.3015](#). [PMID 17883909](#).
16. [Jump up](#) [^] Young WF (2011). "Chapter 11: Shock". In Roger L. Humphries RL; Stone CK. *CURRENT Diagnosis and Treatment Emergency Medicine*., LANGE CURRENT Series (Seventh ed.). McGraw-Hill Professional. [ISBN 0-07-170107-9](#).
17. [Jump up](#) [^] Sheikh, A; ten Broek, Vm; Brown, SG; Simons, FE (24 January 2007). "H1-antihistamines for the treatment of anaphylaxis with and without shock.". *The Cochrane database of systematic reviews* (1): CD006160. [doi:10.1002/14651858.CD006160.pub2](#). [PMID 17253584](#).
18. [Jump up](#) [^] [MedlinePlus Encyclopedia Diphenhydramine Topical](#)
19. [Jump up](#) [^] Aminoff MJ (2012). "Chapter 28. Pharmacologic Management of Parkinsonism & Other Movement Disorders". In Katzung B, Masters S, Trevor A. *Basic & Clinical Pharmacology* (12th ed.). The McGraw-Hill Companies, Inc. pp. 483–500. [ISBN 978-0-07-176401-8](#).
20. [Jump up](#) [^] Kristi Monson; Arthur Schoenstadt (8 September 2013). "[Benadryl Addiction](#)". *eMedTV*.
21. [Jump up](#) [^] Dinndorf PA, McCabe MA, Friedrich S (August 1998). "Risk of abuse of diphenhydramine in children and adolescents with chronic illnesses". *J. Pediatr.* **133** (2): 293–5. [doi:10.1016/S0022-3476\(98\)70240-9](#). [PMID 9709726](#).
22. [Jump up](#) [^] Zachary Flake; Robert Scalley; Austin Bailey (1 March 2004). "[Practical Selection of Antiemetics](#)". *American Family Physician*. Retrieved 10 March 2016.
23. [Jump up](#) [^] "[Diphenhydramine Side Effects](#)". *Drugs.com*. Retrieved 6 April 2009.
24. [^] [Jump up to: ^a ^b ^c](#) Brunton L, Chabner B, Knollmann B (2011). "Chapter 32. Histamine, Bradykinin, and Their Antagonists". In Brunton L. *Goodman & Gilman's The Pharmacological Basis of Therapeutics* (12e ed.). McGraw Hill. pp. 242–245. [ISBN 978-0-07-162442-8](#).
25. [^] [Jump up to: ^a ^b](#) Manning B (2012). "Chapter 18. Antihistamines". In Olson K. [Poisoning & Drug Overdose](#) (6th ed.). McGraw-Hill. [ISBN 978-0-07-166833-0](#). Retrieved 19 March 2013.
26. [Jump up](#) [^] Khalifa M; Drolet B; Daleau P; Lefez C; Gilbert M; Plante S; O'Hara GE; Gleton O; Hamelin BA & Turgeon J. "Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine". *J Pharmacol Exp Ther.* **288**: 858–65. [PMID 9918600](#).
27. [Jump up](#) [^] Cole JB; Stellpflug SJ; Gross EA & Smith SW. "Wide complex tachycardia in a pediatric diphenhydramine overdose treated with sodium bicarbonate". *Pediatr Emerg Care.* **27**: 1175–7. [doi:10.1097/PEC.0b013e31823b0e47](#). [PMID 22158278](#).
28. [Jump up](#) [^] Heine A (November 1996). "Diphenhydramine: a forgotten allergen?". *Contact Derm.* **35** (5): 311–2. [doi:10.1111/j.1600-0536.1996.tb02402.x](#). [PMID 9007386](#).
29. [Jump up](#) [^] Coskey RJ (February 1983). "Contact dermatitis caused by diphenhydramine hydrochloride". *J. Am. Acad. Dermatol.* **8** (2): 204–6. [doi:10.1016/S0190-9622\(83\)70024-1](#). [PMID 6219138](#).
30. [^] [Jump up to: ^a ^b](#) de Leon J, Nikoloff DM (February 2008). "Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports". *CNS Spectr.* **13** (2): 133–5. [PMID 18227744](#).
31. [Jump up](#) [^] Salahudeen MJ; Duffull SB; Nishtala PS; et al. (25 March 2015). "[Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review](#)". *BMC Geriatrics*. **15** (31). [doi:10.1186/s12877-015-0029-9](#). [PMC 4377853](#) . [PMID 25879993](#).
32. [Jump up](#) [^] *Medical Economics* (2000). *Physicians' Desk Reference for Nonprescription Drugs and Dietary Supplements, 2000* (21st ed.). Montvale, NJ: Medical Economics Company. [ISBN 1-56363-341-8](#).

33. [Jump up](#) ^ Schroeck, JL; Ford, J; Conway, EL; Kurtzhals, KE; Gee, ME; Vollmer, KA; Mergenhausen, KA (November 2016). "Review of Safety and Efficacy of Sleep Medicines in Older Adults.". *Clinical therapeutics*. **38** (11): 2340–2372. doi:[10.1016/j.clinthera.2016.09.010](https://doi.org/10.1016/j.clinthera.2016.09.010). PMID [27751669](https://pubmed.ncbi.nlm.nih.gov/27751669/).
34. [Jump up](#) ^ "[High risk medications as specified by NCOA's HEDIS Measure: Use of High Risk Medications in the Elderly](#)" (PDF). National Committee for Quality Assurance (NCQA). Archived from [the original](#) (pdf) on 1 February 2010.
35. [Jump up](#) ^ "[2012 AGS Beers List](#)" (PDF). The American Geriatrics Society. Retrieved 27 November 2015.
36. [Jump up](#) ^ Black RA, Hill DA (June 2003). "Over-the-counter medications in pregnancy". *Am. Fam. Physician*. **67** (12): 2517–24. PMID [12825840](https://pubmed.ncbi.nlm.nih.gov/12825840/).
37. [Jump up](#) ^ Spencer JP, Gonzalez LS, Barnhart DJ (July 2001). "Medications in the breast-feeding mother". *Am. Fam. Physician*. **64** (1): 119–26. PMID [11456429](https://pubmed.ncbi.nlm.nih.gov/11456429/).
38. [Jump up](#) ^ [American Academy of Hospice and Palliative Medicine](#), "[Five Things Physicians and Patients Should Question](#)", [Choosing Wisely: an initiative of the ABIM Foundation](#), [American Academy of Hospice and Palliative Medicine](#), retrieved 1 August 2013, which cites
 - Smith TJ, Ritter JK, Poklis JL, Fletcher D, Coyne PJ, Dodson P, Parker G (2012). "ABH Gel is Not Absorbed from the Skin of Normal Volunteers". *Journal of Pain and Symptom Management*. **43** (5): 961–966. doi:[10.1016/j.jpainsymman.2011.05.017](https://doi.org/10.1016/j.jpainsymman.2011.05.017). PMID [22560361](https://pubmed.ncbi.nlm.nih.gov/22560361/).
 - Weschules DJ (2005). "Tolerability of the Compound ABHR in Hospice Patients". *Journal of Palliative Medicine*. **8** (6): 1135–1143. doi:[10.1089/jpm.2005.8.1135](https://doi.org/10.1089/jpm.2005.8.1135). PMID [16351526](https://pubmed.ncbi.nlm.nih.gov/16351526/).
39. ^ [Jump up to: ^a ^b ^c](#) Pragst F (2007). "Chapter 13: High performance liquid chromatography in forensic toxicological analysis". In Smith RK, Bogusz MJ. *Forensic Science (Handbook of Analytical Separations)*. **6** (2nd ed.). Amsterdam: Elsevier Science. p. 471. ISBN [978-0-444-52214-6](https://www.isbn-international.org/product/978-0-444-52214-6).
40. [Jump up](#) ^ Rogers SC, Pruitt CW, Crouch DJ, Caravati EM (September 2010). "Rapid urine drug screens: diphenhydramine and methadone cross-reactivity". *Pediatr. Emerg. Care*. **26** (9): 665–6. doi:[10.1097/PEC.0b013e3181f05443](https://doi.org/10.1097/PEC.0b013e3181f05443). PMID [20838187](https://pubmed.ncbi.nlm.nih.gov/20838187/).
41. ^ [Jump up to: ^a ^b](#) Khilnani and Khilnani (October 2011). "[Inverse agonism and its therapeutic significance](#)". *Indian J Pharmacol*. **43** (5): 492–501. doi:[10.4103/0253-7613.84947](https://doi.org/10.4103/0253-7613.84947). PMC [3195115](https://pubmed.ncbi.nlm.nih.gov/3195115/) . PMID [22021988](https://pubmed.ncbi.nlm.nih.gov/22021988/).
42. [Jump up](#) ^ Lopez AM (10 May 2010). "[Antihistamine Toxicity](#)". Medscape Reference. WebMD LLC.
43. [Jump up](#) ^ Kim YS, Shin YK, Lee C, Song J (October 2000). "Block of sodium currents in rat dorsal root ganglion neurons by diphenhydramine". *Brain Research*. **881** (2): 190–8. doi:[10.1016/S0006-8993\(00\)02860-2](https://doi.org/10.1016/S0006-8993(00)02860-2). PMID [11036158](https://pubmed.ncbi.nlm.nih.gov/11036158/).
44. ^ [Jump up to: ^a ^b ^c](#) Domino EF (1999). "History of modern psychopharmacology: a personal view with an emphasis on antidepressants". *Psychosom. Med*. **61** (5): 591–8. doi:[10.1097/00006842-199909000-00002](https://doi.org/10.1097/00006842-199909000-00002). PMID [10511010](https://pubmed.ncbi.nlm.nih.gov/10511010/).
45. [Jump up](#) ^ Carr KD, Hiller JM, Simon EJ (February 1985). "Diphenhydramine potentiates narcotic but not endogenous opioid analgesia". *Neuropeptides*. **5** (4–6): 411–4. doi:[10.1016/0143-4179\(85\)90041-1](https://doi.org/10.1016/0143-4179(85)90041-1). PMID [2860599](https://pubmed.ncbi.nlm.nih.gov/2860599/).
46. [Jump up](#) ^ Hevesi D (29 September 2007). "[George Rieveschl, 91, Allergy Reliever, Dies](#)". *The New York Times*. Retrieved 14 October 2008.
47. [Jump up](#) ^ "[Benadryl](#)". Ohio History Central. Retrieved 13 August 2015.
48. [Jump up](#) ^ Ritchie J (24 September 2007). "[UC prof, Benadryl inventor dies](#)". *Business Courier of Cincinnati*. Retrieved 14 October 2008.
49. [Jump up](#) ^ Awdishn RA, Whitmill M, Coba V, Killu K (October 2008). "[Serotonin reuptake inhibition by diphenhydramine and concomitant linezolid use can result in serotonin syndrome](#)". *Chest*. **134** (4 Meeting abstracts). doi:[10.1378/chest.134.4_MeetingAbstracts.c4002](https://doi.org/10.1378/chest.134.4_MeetingAbstracts.c4002).
50. [Jump up](#) ^ Barondes SH (2003). *Better Than Prozac*. New York: Oxford University Press. pp. 39–40. ISBN [0-19-515130-5](https://www.isbn-international.org/product/0-19-515130-5).
51. [Jump up](#) ^ "[Diphenhydramine and Alcohol / Food Interactions](#)". *Drugs.com*.
52. [Jump up](#) ^ Zimatkin SM, Anichtchik OV (1999). "Alcohol-histamine interactions". *Alcohol Alcohol*. **34** (2): 141–7. doi:[10.1093/alcalc/34.2.141](https://doi.org/10.1093/alcalc/34.2.141). PMID [10344773](https://pubmed.ncbi.nlm.nih.gov/10344773/).
53. [Jump up](#) ^ Sandor I (30 July 2000). "[Using Antihistamines, Anticholinergics, and Depressants To Potentiate Opiates, And Dealing With Opiate Side Effects](#)". *Antihistamine Aficionado Magazine*.

54. [Jump up](#) ^ Food and Drug Administration, HHS (2002). "[Labeling of Diphenhydramine-Containing Drug Products for Over-the-Counter Human Use](#)". *Federal Register*. **67** (235): 72555–9. [PMID 12474879](#). Retrieved 14 October 2008.
55. [Jump up](#) ^ Marinetti L, Lehman L, Casto B, Harshbarger K, Kubiczek P, Davis J (October 2005). "Over-the-counter cold medications-postmortem findings in infants and the relationship to cause of death". *J. Anal. Toxicol.* **29** (7): 738–43. [doi:10.1093/jat/29.7.738](#). [PMID 16419411](#).
56. [Jump up](#) ^ Baselt RC (2008). *Disposition of Toxic Drugs and Chemicals in Man*. Biomedical Publications. pp. 489–492. [ISBN 0-9626523-7-7](#).
57. [Jump up](#) ^ "[List of prohibited and controlled drugs according to chapter 96 of the laws of Zambia](#)" (DOC). The Drug Enforcement Commission ZAMBIA.
58. [Jump up](#) ^ "[Zambia](#)". Country Information > Zambia. Bureau of Consular Affairs, U.S. Department of State. Retrieved 17 July 2015.
59. [Jump up](#) ^ "[Is P&G Preparing to Expand ZzzQuil?](#)". Retrieved 2017-02-10.
60. [Jump up](#) ^ Forest E (27 July 2008). "[Atypical Drugs of Abuse](#)". Articles & Interviews. Student Doctor Network.
61. [Jump up](#) ^ "[Diphenhydramine overdose](#)". MedlinePlus Medical Encyclopedia. U.S. National Library of Medicine.

Source: <https://en.wikipedia.org/wiki/Diphenhydramine>